HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study
Authors:
- Delta Coordinating CommitteeDCDelta Coordinating Committee
- Delta Virology CommitteeDCDelta Virology Committee
- 1 January 1999
- journal article
- clinical trial
- Published by Wolters Kluwer Health in AIDS
- Vol. 13 (1) , 57-65
Abstract
To assess changes in HIV RNA and their relationship to disease progression. Delta was a randomized double-blind trial comparing zidovudine (ZDV) monotherapy with ZDV plus didanosine (ddI) or ZDV plus zalcitabine (ddC). Participants had AIDS (with CD4 cell counts above 50 x 10(6)/l), AIDS-related complex, or were asymptomatic with CD4 cell counts below 350 x 10(6)/l. The trial included both ZDV-naive and ZDV-experienced participants. A total of 1280 participants in the Delta trial whose serum samples had been stored at -70 degrees C and who had a minimum of one sample taken before the start of treatment and at least one later sample. HIV-1 RNA quantification was performed using the nucleic acid sequence-based amplification HIV-1 RNA quantitative assay with a cut-off of 800 copies/ml. Reductions in HIV RNA by treatment group were consistent with the clinical results; in ZDV-naive participants the maximum median fall occurred at 4 weeks for all three groups (ZDV, 0.54 log10 copies/ml; ZDV-ddI, 1.38 log10 copies/ml; ZDV-ddC, 1.31 log10 copies/ml). On average the reductions were smaller in ZDV-experienced participants but the difference between the monotherapy and combination arms was very similar in ZDV-naive and experienced participants. Baseline HIV RNA levels, adjusted for CD4 cell counts were highly predictive of time to virological response (HIV RNA < 800 copies/ml); HIV RNA nadirs achieved were predictive of survival. Viral load rebound following response was independent of treatment group and previous ZDV therapy. Virological changes in response to treatment are of value in assessing prognosis and the activity of new therapies; in particular, there is a strong association between the minimum HIV RNA achieved in the first 16 weeks and subsequent clinical response. CD4 cell counts are independently predictive of response.Keywords
This publication has 13 references indexed in Scilit:
- A Critical Assessment of the Prognostic Value of HIV-1 RNA Levels and CD4+ Cell Counts in HIV-Infected PatientsArchives of internal medicine (1960), 1998
- Prognostic Indicators for AIDS and Infectious Disease Death in HIV-Infected Injection Drug UsersJAMA, 1998
- HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trialThe Lancet, 1997
- Prognostic Value of Serum HIV-RNA Levels at Virologic Steady State After Seroconversion: Relation to CD4 Cell Count and Clinical Course of Primary InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 1997
- Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasmaJournal of Clinical Microbiology, 1996
- The Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in HIV-Infected Adults with 200 to 500 CD4 Cells per Cubic MillimeterNew England Journal of Medicine, 1996
- Prognostic Value of Plasma Human Immunodeficiency Virus Type 1 (HIV-l) RNA Levels in Patients with Advanced HIV-l Disease and with Little or No Prior Zidovudine TherapyThe Journal of Infectious Diseases, 1996
- Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individualsThe Lancet, 1996
- Serum HIV-1 RNA Levels and Time to Development of AIDS in the Multicenter Hemophilia Cohort StudyJAMA, 1996
- HIV-1 RNA levels and the development of clinical diseaseAIDS, 1996